search
Back to results

Impact of Antioxidant Juice Intake on Brain Injury and Placental Pathology in Infants With Intrauterine Growth Restriction (IUGR)

Primary Purpose

Intrauterine Growth Restriction

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Pomegranate Juice
Placebo Juice
Sponsored by
Brigham and Women's Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Intrauterine Growth Restriction

Eligibility Criteria

18 Years - 45 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

- Expecting mother with a fetal diagnosis of less than 5th percentile on the Doubilet fetal growth curve

Exclusion Criteria:

  • Multiple congenital abnormalities
  • Known fetal chromosomal disorder
  • Maternal illicit drug or alcohol intake

Sites / Locations

  • Brigham and Women's Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Pomegranate Juice

Placebo Juice

Arm Description

Dietary supplementation with 8 oz. commercially-available pomegranate juice consumed daily.

Dietary supplementation with 8 oz. placebo juice (identical to pomegranate juice but lacking polyphenols) consumed daily.

Outcomes

Primary Outcome Measures

Infant brain injury assessed on term-equivalent brain magnetic resonance image (MRI) using the Kidokoro injury scoring system.
The Kidokoro scale is a comprehensive, objective scoring system for classifying the nature and extent of neonatal brain injury on MRI (Kidokoro et al. American Journal of Neuroradiology. 2013; 34(11):2208-14).
Total and regional infant brain volumes assessed on term equivalent brain MRI using MANTiS.
MANTiS (Morphologically Adaptive Neonatal Tissue Segmentation) describes neonate-specific brain tissue segmentation into 8 categories using Statistical Parametric Mapping (SPM) software (Beare et al. Frontiers in Neuroinformatics. 2016;10:12).
Diffusion tensor imaging measures of fractional anisotropy (FA), and mean (MD), radial (RD), and axial (AD) diffusivity from infant term equivalent brain MRI.
FA, MD, RD, and AD will be measured from a diffusion-weighted sequence on brain MRI.

Secondary Outcome Measures

Cognitive, motor, and language neurodevelopment scores on the Bayley III exam.
The Bayley Scores of Infant and Toddler Development (Edition III) is a comprehensive examination tool used to assess neurodevelopment in infants and toddlers up to 42 months.
Maternal compliance with juice regimen.
Maternal compliance with the assigned juice regimen is assessed by participant logbook record and assessment of change in polyphenols (urolithin A and dimethylellagic glucuronide concentration, ng/mL) in maternal urine and blood at enrollment and in maternal urine, blood and cord blood at the time of delivery.

Full Information

First Posted
May 11, 2020
Last Updated
July 5, 2023
Sponsor
Brigham and Women's Hospital
Collaborators
University of California, Los Angeles, POM Wonderful LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT04394910
Brief Title
Impact of Antioxidant Juice Intake on Brain Injury and Placental Pathology in Infants With Intrauterine Growth Restriction (IUGR)
Official Title
Impact of Antioxidant Juice Intake on Brain Injury and Placental Pathology in Infants With Intrauterine Growth Restriction (IUGR)
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Completed
Study Start Date
January 16, 2016 (Actual)
Primary Completion Date
January 1, 2022 (Actual)
Study Completion Date
February 26, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Brigham and Women's Hospital
Collaborators
University of California, Los Angeles, POM Wonderful LLC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Infants diagnosed with intrauterine growth restriction are at increased risk for brain injury in the neonatal period, and eventually increased risk for adverse long-term neurodevelopmental outcomes. This kind of growth restriction is often caused by long-term placental insufficiency leading to chronic lack of oxygen in the brain during development. Pomegranate juice is one of the highest polyphenol-containing dietary supplements commercially available. Previous studies have shown that pomegranate-derived polyphenols are potent neuroprotective antioxidants with no proven side effects. The investigators hypothesize that maternal dietary supplementation with pomegranate juice during the last trimester of pregnancy will reduce the effects of exogenous stimuli contributing to placental insufficiency, and will enhance brain growth and development in the IUGR population.
Detailed Description
The current study seeks to investigate the impact of maternal dietary supplementation with pomegranate juice on placental morphology and on subsequent newborn brain development and function. A total of 99 consenting women carrying fetuses with a diagnosis of intrauterine growth restriction (IUGR) in the third trimester were randomized to one of two arms. Treatment Group: Expecting mothers in this group will be randomized to consume 8oz of pomegranate juice daily. Participants will keep a daily diary documenting compliance with the regimen. Participants will continue daily intake until delivery. Placebo group: Expecting mothers will be randomized to consume an 8oz of pomegranate free juice placebo that matches taste, calories, and appearance to regular pomegranate juice but lacks polyphenols. Participants will keep a diary of daily intake to help ensure compliance similar to the treatment group. Participants will continue to placebo until delivery. Both groups: Maternal blood and urine samples will be collected prior to starting the juice regimen in order to establish baseline metabolite status. For the first 84 mothers enrolled, a fetal MRI was scheduled prior to beginning the juice regimen. Phase I participants will undergo two fetal echocardiograms: one before starting the juice regimen, and a second two weeks into the juice regimen to establish the safety of high polyphenol intake on fetal heart development. All women will be contacted on a weekly basis to assess compliance. At the time of delivery, maternal blood and urine, and cord blood will be collected and sent for analysis to test for the presence of dimethylellagic acid glucuronide (DMEAG) and urolithin A glucuronide (UAG), polyphenic components of pomegranate juice. Placental material will be sent for formal pathological exam. If clinically stable, MRI will be undertaken without sedation at term equivalent (38-41 weeks CGA). Infants will undergo testing of cognitive, gross and fine motor, and speech skills at around 2 years of age.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Intrauterine Growth Restriction

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
103 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Pomegranate Juice
Arm Type
Experimental
Arm Description
Dietary supplementation with 8 oz. commercially-available pomegranate juice consumed daily.
Arm Title
Placebo Juice
Arm Type
Placebo Comparator
Arm Description
Dietary supplementation with 8 oz. placebo juice (identical to pomegranate juice but lacking polyphenols) consumed daily.
Intervention Type
Dietary Supplement
Intervention Name(s)
Pomegranate Juice
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo Juice
Primary Outcome Measure Information:
Title
Infant brain injury assessed on term-equivalent brain magnetic resonance image (MRI) using the Kidokoro injury scoring system.
Description
The Kidokoro scale is a comprehensive, objective scoring system for classifying the nature and extent of neonatal brain injury on MRI (Kidokoro et al. American Journal of Neuroradiology. 2013; 34(11):2208-14).
Time Frame
One time occurrence at birth or term-equivalent age if infant is born preterm.
Title
Total and regional infant brain volumes assessed on term equivalent brain MRI using MANTiS.
Description
MANTiS (Morphologically Adaptive Neonatal Tissue Segmentation) describes neonate-specific brain tissue segmentation into 8 categories using Statistical Parametric Mapping (SPM) software (Beare et al. Frontiers in Neuroinformatics. 2016;10:12).
Time Frame
One time occurrence at birth or term-equivalent age if infant is born preterm.
Title
Diffusion tensor imaging measures of fractional anisotropy (FA), and mean (MD), radial (RD), and axial (AD) diffusivity from infant term equivalent brain MRI.
Description
FA, MD, RD, and AD will be measured from a diffusion-weighted sequence on brain MRI.
Time Frame
One time occurrence at birth or term-equivalent age if infant is born preterm.
Secondary Outcome Measure Information:
Title
Cognitive, motor, and language neurodevelopment scores on the Bayley III exam.
Description
The Bayley Scores of Infant and Toddler Development (Edition III) is a comprehensive examination tool used to assess neurodevelopment in infants and toddlers up to 42 months.
Time Frame
The Bayley III exam will be administered at a one-time visit scheduled between 18-36 months.
Title
Maternal compliance with juice regimen.
Description
Maternal compliance with the assigned juice regimen is assessed by participant logbook record and assessment of change in polyphenols (urolithin A and dimethylellagic glucuronide concentration, ng/mL) in maternal urine and blood at enrollment and in maternal urine, blood and cord blood at the time of delivery.
Time Frame
Comparison of one pre-juice regimen UA and DMEAG concentration measurement (ng/mL) to one post-juice regimen blood and urine concentration measurement (ng/mL) collected at the time of delivery.
Other Pre-specified Outcome Measures:
Title
Placental weight.
Description
Weight of the placenta measured in grams.
Time Frame
The placenta will be weighed as part of routine pathology exam within 1-3 days of delivery.
Title
Incidence of pre-eclampsia.
Description
Incidence of pre-eclampsia requiring medication as documented in the medical record.
Time Frame
The electronic medical record will be reviewed within 1 week of delivery.
Title
Gestational age at delivery.
Description
Gestational age at delivery based on ultrasound dating acquired at less than 12 weeks' gestation as documented in the medical record.
Time Frame
The electronic medical record will be reviewed within 1 week of delivery.
Title
Incidence of resuscitation at delivery.
Description
Incidence of infant resuscitation at delivery measured by APGAR scores assigned at birth and documented in the medical record.
Time Frame
The electronic medical record will be reviewed within 1 week of delivery.
Title
Cord gas characteristics.
Description
Umbilical artery cord gas pH and base deficit as documented in the medical record.
Time Frame
The electronic medical record will be reviewed within 1 week of delivery.

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: - Expecting mother with a fetal diagnosis of less than 5th percentile on the Doubilet fetal growth curve Exclusion Criteria: Multiple congenital abnormalities Known fetal chromosomal disorder Maternal illicit drug or alcohol intake
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Terrie E Inder, MD, MBChB
Organizational Affiliation
Brigham and Women's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Brigham and Women's Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Individual participant data (IPD) cannot be shared publicly because the investigators had not previously sought Institutional Review Board (IRB) approval for public sharing of participant data as part of the informed consent process. However, the investigators will gladly share with any investigator the de-identified minimal raw data set needed to replicate the study upon request.
Citations:
PubMed Identifier
33574371
Citation
Ross MM, Cherkerzian S, Mikulis ND, Turner D, Robinson J, Inder TE, Matthews LG. A randomized controlled trial investigating the impact of maternal dietary supplementation with pomegranate juice on brain injury in infants with IUGR. Sci Rep. 2021 Feb 11;11(1):3569. doi: 10.1038/s41598-021-82144-0.
Results Reference
derived

Learn more about this trial

Impact of Antioxidant Juice Intake on Brain Injury and Placental Pathology in Infants With Intrauterine Growth Restriction (IUGR)

We'll reach out to this number within 24 hrs